1/6
08:46 am
bdrx
Biodexa Pharmaceuticals promotes Fiona Sharp to CFO, secretary [Yahoo! Finance]
Low
Report
Biodexa Pharmaceuticals promotes Fiona Sharp to CFO, secretary [Yahoo! Finance]
1/5
09:15 am
bdrx
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary [Yahoo! Finance]
Low
Report
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary [Yahoo! Finance]
1/5
08:30 am
bdrx
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary
Low
Report
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary
12/27
01:05 am
bdrx
Biodexa Pharmaceuticals (NASDAQ:BDRX) was upgraded by analysts at
Wall S
High
Report
Biodexa Pharmaceuticals (NASDAQ:BDRX) was upgraded by analysts at
Wall S
12/18
08:30 am
bdrx
Biodexa Announces Pricing of $10 Million Public Offering
High
Report
Biodexa Announces Pricing of $10 Million Public Offering
12/1
08:30 am
bdrx
Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
Medium
Report
Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
11/24
08:30 am
bdrx
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
Low
Report
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
11/7
01:12 am
bdrx
Biodexa Pharmaceuticals (NASDAQ:BDRX) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Biodexa Pharmaceuticals (NASDAQ:BDRX) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
11/3
08:30 am
bdrx
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion
Medium
Report
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion
10/27
05:31 pm
bdrx
Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight
Medium
Report
Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight
10/27
05:31 pm
bdrx
Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight
Medium
Report
Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight